Nuvesse Skin Therapies Announces Presentation of Top-line Clinical Data Supporting Ability of Cellulation™ Technology to Actively Deliver Topically Applied Skin Therapies Faster and Deeper

— Data Presented at 73rd Annual American Academy of Dermatology Annual Meeting

CASTRO VALLEY, Calif., March 23, 2015 /PRNewswire/ — Nuvesse Skin Therapies, a leading cosmetic skin care company, today announced the presentation of positive data demonstrating the ability of the company’s CellulationTM Technology to actively deliver topically applied skin therapies into the epidermis. This patented serum technology calms, cools and hydrates after aesthetic medical skin treatments. Nuvesse has incorporated this applied science into an expanded portfolio of products designed to facilitate the passage of beneficial skin care constituents across the tough stratum corneum skin barrier into the epidermis, the source of many skin care concerns.

The data, presented at the 73rd Annual American Academy of Dermatology (AAD) Annual Meeting, are believed to be the first findings demonstrating the ability to deliver large molecules directly into the epidermis intact, without damage to the outermost layer of the skin. Complete data from the trials have been accepted for upcoming publication in a peer-reviewed medical journal.

"The most significant challenge in skin rejuvenation has been to penetrate the stratum corneum and deliver beneficial constituents deeper within the skin where they are most needed. These clinical findings demonstrate the ability of CellulationTM Technology to enhance treatment benefits and aid in the corrective process," said Philip Werschler, M.D., associate clinical professor of medicine/dermatology, University of Washington, and medical director of Nuvesse. "It’s extremely notable that the majority of investigators and patients alike agreed that NuvesseMD products enhanced procedure outcomes, were well-tolerated, easy to use and they would elect to use such products in the future."

Findings presented included topline results from an in-vitro study, demonstrating the proprietary biochemical product formulation and transport delivery by CellulationTM technology, and a multi-center, proof-of-concept IRB approved clinical study evaluating NuvesseMD facial masks in four different treatment protocols in a total of 140 patients. (Translational Technology for Non-Disruptive Stratum Corneum High Molecular Weight Carrier Assist, AAD Poster #1399).

The first clinical protocol evaluated the safety and efficacy of a Nuvesse Serum No. 3 Post Treatment mask used as an adjunctive agent following ablative or fractional ablative laser resurfacing. In this protocol, 100 percent of investigators agreed that patients were healing more quickly than compared to standard post-treatment protocol. Ninety-one percent of physicians agreed they would use the product again, and all agreed that patients were satisfied with the experience of using the mask.

The other three protocols involved the use of a Nuvesse Serum No. 5 Hydrating mask as an adjunctive agent in microdermabrasion and a Serum No. 25 Lip and Serum No. 21 Crow’s Feet Mask as an adjuvant agent for cosmetic facial procedures. In the microdermabrasion protocol, 91 percent of investigators agreed that patients’ erythema resolved more quickly than without use of the mask, and 51 percent of investigators agreed that patient’s fine lines and wrinkles appeared to have improved after just one wearing. Nearly all (97 percent) of investigators reported they would use the product again. In the Lip and Crow’s Feet protocols, 60 percent of investigators agreed or strongly agreed that patients’ fine lines and wrinkles appeared to have improved after only one treatment and 94 percent reported they would use the product again.

"The ability to deliver treatments past the outer layer of the skin deep within the epidermis represents a new generation of skin technology. This technology has applicability both as a stand-alone treatment and to improve existing skin care treatment modalities and topical applications," said Dennis Condon, chief executive officer and co-founder of Nuvesse. "The potential of Cellulation Technology and Nuvesse products in skin care is vast, and we look forward to the continued expansion and introduction of this approach, which has the potential to significantly impact and improve the future of skin care for people worldwide."

About CellulationTM Technology

Cellulation Technology is derived from a wound care application designed to penetrate the stratum corneum in a revolutionary way – transporting large molecules across the outer skin barrier to penetrate into the epidermis. Standard skin care treatments (ablative and non-ablative) primarily involve a healing response and are associated with side effects including swelling and edema. Cellulation Technology, applied in a topical mask or roller application, can deliver molecules through the stratum corneum without injury and is designed to aid in significant skin enhancement.

About Nuvesse Skin Therapies

Nuvesse is a leading cosmetic skin therapy company focused on the advancement of a CellulationTM Technology. The company’s skin therapy serums evolved out of a history of clinically validated wound healing science. It includes science-based serums and infused into biocellulose masks and roller applicators which effectively address skin care concerns such as post-treatment skin, fine lines, and wrinkles. For more information, visit

Media Contact:
Julie Garlikov